Bimekizumab safety in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in phase 2 and 3 clinical trials. (2022). SKIN The Journal of Cutaneous Medicine, 6(6), s66. https://doi.org/10.25251/skin.6.supp.66